Biosyent Inc (BIOYF) 5.4300 $BIOYF
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 1,086%
Marketwired - Thu Sep 17, 8:25AM CDT
Editors Note: There is a photo associated with this press release.
RX.VN: 7.000 (+0.130)
BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada
Marketwired - Wed Aug 19, 7:01AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) announced today that its subsidiary BioSyent Pharma Inc. has signed an agreement with Photocure ASA granting BioSyent the exclusive rights for Cysview(R) in Canada. Cysview(R) (hexaminolevulinate hydro-chloride) is an innovative technology that aids in the diagnosis and management of bladder cancer and was approved by Health Canada in January 2015. It has been successfully marketed in the USA, Europe, and the Nordic region, since 2006. Commercialization of Cysview(R) in Canada will commence this year. Under the terms of the agreement, Photocure will receive up to USD $1,000,000 in milestone payments for the rights to Cysview in Canada, which includes USD $650,000 upon signing of the agreement.
PHO: 22.54 (-0.06), RX.VN: 7.000 (+0.130)
BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
Marketwired - Wed Aug 12, 7:01AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for the three and six months ending June 30, 2015. Key highlights include:
RX.VN: 7.000 (+0.130)
BioSyent: A High Growth Niche Pharma Company With Some Catalysts For Sustainable Performance
Dan Stringer - at Seeking Alpha - Wed Jun 17, 10:05AM CDT
CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 3:22PM CDT
A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The third bullet point previously compared Q1 2015 with Q1 2013 as opposed to Q1 2014. The correct version follows:
RX.VN: 7.000 (+0.130)
BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 7:02AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights include:
RX.VN: 7.000 (+0.130)
BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Fri May 01, 3:02PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2015 Bloom Burton & Co. Healthcare Investor Conference at 9:30am (ET), May 5, 2015 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Mr. Goehrum will provide an overview of the Company and its corporate activities.
RX.VN: 7.000 (+0.130)
BioSyent Comments on Recent Market Activity
Marketwired - Fri Apr 10, 7:01AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) wishes to comment on the unusual recent market activity in its stock. The Company advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price on Thursday, April 9, 2015. The Company looks forward to disclosing its first quarter results on May 13, 2015.
RX.VN: 7.000 (+0.130)
BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
Marketwired - Tue Feb 03, 7:05AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System(R) for pre-filled syringes (PFS), a new urgent care product for use in hospitals and acute care settings.
RX.VN: 7.000 (+0.130)
BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories.
RX.VN: 7.000 (+0.130)
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include:
RX.VN: 7.000 (+0.130)
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 1,086%
Marketwired - Thu Sep 17, 8:25AM CDT
Editors Note: There is a photo associated with this press release.
RX.VN: 7.000 (+0.130)
BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada
Marketwired - Wed Aug 19, 7:01AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) announced today that its subsidiary BioSyent Pharma Inc. has signed an agreement with Photocure ASA granting BioSyent the exclusive rights for Cysview(R) in Canada. Cysview(R) (hexaminolevulinate hydro-chloride) is an innovative technology that aids in the diagnosis and management of bladder cancer and was approved by Health Canada in January 2015. It has been successfully marketed in the USA, Europe, and the Nordic region, since 2006. Commercialization of Cysview(R) in Canada will commence this year. Under the terms of the agreement, Photocure will receive up to USD $1,000,000 in milestone payments for the rights to Cysview in Canada, which includes USD $650,000 upon signing of the agreement. PHO: 22.54 (-0.06), RX.VN: 7.000 (+0.130)
BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
Marketwired - Wed Aug 12, 7:01AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for the three and six months ending June 30, 2015. Key highlights include: RX.VN: 7.000 (+0.130)
BioSyent: A High Growth Niche Pharma Company With Some Catalysts For Sustainable Performance
Dan Stringer - at Seeking Alpha - Wed Jun 17, 10:05AM CDT
CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 3:22PM CDT
A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The third bullet point previously compared Q1 2015 with Q1 2013 as opposed to Q1 2014. The correct version follows:
RX.VN: 7.000 (+0.130)
BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 7:02AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights include: RX.VN: 7.000 (+0.130)
BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Fri May 01, 3:02PM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2015 Bloom Burton & Co. Healthcare Investor Conference at 9:30am (ET), May 5, 2015 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Mr. Goehrum will provide an overview of the Company and its corporate activities. RX.VN: 7.000 (+0.130)
BioSyent Comments on Recent Market Activity
Marketwired - Fri Apr 10, 7:01AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) wishes to comment on the unusual recent market activity in its stock. The Company advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price on Thursday, April 9, 2015. The Company looks forward to disclosing its first quarter results on May 13, 2015. RX.VN: 7.000 (+0.130)
BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
Marketwired - Tue Feb 03, 7:05AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System(R) for pre-filled syringes (PFS), a new urgent care product for use in hospitals and acute care settings. RX.VN: 7.000 (+0.130)
BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories. RX.VN: 7.000 (+0.130)
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include: RX.VN: 7.000 (+0.130)
